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Abstract
Introduction: Obesity is a major and challenging public health problem. The aim of this substudy is to
evaluate the effect of calcium supplementation on body weight in women recruited in the Calcium and
Preeclampsia trial.
Methods: Women were recruited before pregnancy and randomized to receive a calcium supplement
containing 500 mg of elemental calcium or placebo until 20 weeks’ gestation; all women received 1.5 g
from 20 weeks until delivery.
Results: A total of 630 women conceived during the study, 322 allocated to calcium and 308 to
placebo. Among these, 230 allocated to calcium and 227 allocated to placebo had information on body
weight at baseline and at 8 weeks’ gestation. During the study period, women allocated to calcium had
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a mean weight increase of 1.1 (SD +5.5) kg, whereas those allocated to placebo had a mean increase
of 1.5 (SD +6.1) kg, a mean difference of 0.4 kg (95% 0.4 (1.4 to 0.6); P ¼ .408). Women classified
as obese at the start of the trial had a lower body weight gain at 8 weeks’ gestation (1.0 kg; 95% CI:
3.2 to 1.2; P ¼ .330) and at 32 weeks’ gestation (2.1 kg; 95% CI: 5.6-1.3; P ¼ .225) if they received
calcium as compared to placebo. However, none of these differences were statistically significant.
Conclusion: The smaller increase in body weight found in women supplemented with 500 mg ele-
mental calcium daily is quantitatively consistent with previous studies. However, in this study, the dif-
ference was not statistically significant.
Keywords
obesity, calcium, pregnancy, supplementation, body mass index
Introduction
Obesity represents a major and challenging public
health problem as it increases the risk of develop-
ing high blood pressure, insulin resistance, heart
disease, diabetes, osteoarthritis, and sleep
apnoea.1,2 During pregnancy, obesity increases
the risk of adverse pregnancy outcomes.1,3 Obe-
sity before and during pregnancy increases the
risks of gestational diabetes and hypertension,
mental ill health before and after pregnancy, cesar-
ean section, preterm birth, large for gestational
age, miscarriage, stillbirth, and fetal death.4 It has
been estimated that a higher 5 to 7 kg/m2 body
mass prepregnancy index (BMI) doubles the risk
of preeclampsia.5,6 Even an increase of 1 or 2 BMI
units between pregnancies increases the risk of
hypertension and gestational diabetes.7
Several studies have investigated the modulat-
ing effect of calcium intake upon body weight.8 In
animal models, changes in lipid metabolism with
calcium supplementation have been shown.9,10 In
addition, after induced weight loss, obese mice on
a diet low in calcium experienced increased lipo-
genesis and rapid bodyweight regain, whereas cal-
cium supplementation inhibited weight regain.11
In order to improve pregnancy outcomes, over-
weight and obese women are advised to lose
weight before conception; however, the evidence
on how to achieve this is scarce.7 Also, for over-
weight or obese pregnant women, there is little
evidence on how to manage their weight during
pregnancy.7,12 Until more robust evidence is avail-
able, recommendations are to gain weight,
although at a reduced rate, as dieting during
pregnancy may increase the risk of ketosis that is
harmful to the fetus. The US Institute of Medicine
Guidelines recommend that women who are over-
weight should aim to gain 7 to 11.5 kg, and women
who are obese should aim to gain 5 to 9 kg during
the entire pregnancy.13
The Calcium and Preeclampsia (CAP) trial was
a randomized controlled trial (RCT) conducted
between 2011 and 2017 which aimed to test the
effect of calcium supplementation commencing
before pregnancy and continued up to 20 weeks’
gestation on the incidence of preeclampsia in
women with a history of preeclampsia.14 Nested
in the CAP trial, the aim of this substudy was to
evaluate the effect of calcium supplementation on
body weight in women at 8, 20 and 32 weeks’
gestation recruited in this trial.
Methods
The protocol of the multicenter CAP trial has been
previously published.14 The trial included women
at high risk of preeclampsia from South Africa,
Zimbabwe, and Argentina. Briefly, women were
recruited before pregnancy and randomized to
receive until 20 weeks’ gestation a calcium sup-
plement containing 500 mg of elemental calcium
as calcium carbonate or placebo identical in shape,
color, and taste to the calcium tablet. Women were
asked to chew the tablet during the day, not close
in time to taking food or iron supplements. Fol-
lowing World Health Organization’s (WHO) rec-
ommendations, from 20 weeks’ gestation until
delivery, all women received calcium supplemen-
tation (1.5 g).15 The trial recruited participants
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from July 12, 2011, to September 8, 2016. For the
substudy presented here, our sample included all
participants of the CAP trial with information on
body weight registered at baseline and at 8 weeks
of pregnancy.
Sample Size
The CAP trial recruited 540 women with a preg-
nancy of more than 20 weeks.16 Of those, 457
women had information on body weight at 8
weeks’ gestation and were used for the analysis
of this substudy.
Measurements
Data collected at recruitment and used for the anal-
ysis of this substudy included maternal age, height
and weight, country of residence, number of previ-
ous pregnancies, and date of birth of the last preg-
nancy complicated with preeclampsia. For women
who became pregnant, weight during pregnancy
was recorded at 8, 20, and 32 weeks’ gestation dur-
ing the scheduled trial follow-up visits. Compli-
ance to the study supplements was measured at
each follow-up visit. Participants were asked to
bring the study bottle to each visit and the remain-
ing supplements were recorded. In those cases
where thewomandidnotbring thebottle, theywere
phoned to assess the number of supplements taken.
Compliance was calculated as a percentage of the
number of used supplements of the total number of
supplements that should have been taken from the
start of the trial until 20 weeks’ gestation.
Research nurses specially trained for the CAP
trial assessed all anthropometric and clinical mea-
surement at admission (when women joined the
study, were randomized, and started calcium and
placebo supplementation) and during follow-up
visits at each participating site.
Bodyweight was measured to the nearest 0.1
kg. Women were measured in light clothing and
without shoes. Height was measured to the near-
est 1 cm using a stadiometer while the participant
was not wearing shoes. Scales and stadiometers
were those provided by each hospital and
remained the same throughout the study. The
Manual of Operations and the Standard Operating
Procedures provided instructions on how women
should be weighed and measured.
Prepregnancy BMI was calculated as weight
(kg) divided by the square of the body height (m)
using measurements recorded at admission.
Women were classified according to the WHO
BMI standards for adults, defined as underweight
(BMI < 18.5), normal (18.5  BMI < 25), over-
weight (BMI25and<30),orobese(BMI30).17
Dietary energy and calcium intakes were mea-
sured at 20 weeks’ gestation using a triple-pass 24-
hour recall adapted from the method developed by
Nelson et al.18 Before the first CAP trial interview,
it was pilot tested in Argentina, South Africa, and
Zimbabwe.19
Analysis
Baseline data were compared between the calcium
and placebo groups for the population included in
this subanalysis (women who were randomized at
admission, became pregnant, and had weight mea-
surements at 8 weeks’ gestation). We used an
intention-to-treat approach for this analysis as rec-
ommended by the Consolidated Standards of
Reporting Trials (CONSORT) guidelines.20
Continuous variables were described with
means and SDs and categorical variables with per-
centages. To evaluate the effect of calcium on body
weight, we analyzed the information collected
from randomization to 8 weeks’ gestation as we
did not have further weight measurements after
randomization and before pregnancy. We used
weight at 8 weeks’ gestation as a surrogate of pre-
conceptual body weight. Evidence from a pub-
lished cross-sectional study of 1000 women
shows there isnosignificant change inmeanmater-
nal body weight or BMI in the first trimester.21
We evaluated the effect of calcium supplemen-
tation on body weight at 20 weeks’ gestation as the
difference between weight at admission to the
study and weight at 20 weeks’ gestation as all
women began a similar calcium intake at 20 weeks’
gestation until the end of pregnancy. We also eval-
uated any difference at 32 weeks’ gestation. To
compare continuous variables between the inter-
vention and control groups, a t test was used, and to
compare categorical values, a w2 test was used.
We then performed the same analysis of the
effect of calcium supplementation at 8, 20, and 32
weeks’ gestation for the following 3 BMI
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classification groups: underweight or normal,
overweight, and obese. To explore the effect in
compliant women, a subgroup analysis was con-
ducted for women with compliance 80% or
higher from admission to the corresponding
follow-up visit.
Finally, as the time between admission and
pregnancy was different for each woman, we eval-
uated the effect of calcium supplementation from
admission to 8 weeks’ gestation according to the
numberofmonthsofsupplementation.Onthebasis
of the literature, we proposed 3 groups in terms of
the lengthof thecalciumsupplementation: (1) from
2 to less than 6 months, (2) from 6 to less than 12
months, and (3) more than 12 months, as there are
studies showing effect with a duration between 2
and 6 months; however, there are no studies with
a duration of less than 2 months and very few of
more than 6 months. A P value of .05 was used to
define significant differences. Statistical analysis
was performed with SPSS version 21.
Results
A total of 1355 women participated in the CAP
study and were randomized to receive calcium
Figure 1. Women for the analysis of the effect of calcium on weight.
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(n ¼ 678) or placebo (n ¼ 677; see Figure 1). Of
those, 630 women conceived during the study,
with 322 in the calcium group and 308 in the pla-
cebo. Of these, 230 allocated to calcium and 227
allocated to placebo had information on body
weight at 8 weeks’ gestation, 198 allocated to cal-
cium and 198 allocated to placebo had information
on body weight at 20 weeks’ gestation, and 142
allocated to calcium and 139 allocated to placebo
had information on body weight at 32 weeks’
gestation. None of the participants required to
interrupt calcium or placebo supplementation due
to adverse events.
Baseline characteristics of all randomized
women and women included in this substudy are
illustrated in Table 1. We did not find any relevant
difference at baseline in any of the variables
between those allocated to calcium and placebo
in any of the groups nor any difference between
groups. The average duration of calcium or pla-
cebo supplementation from recruitment at base-
line to 8 weeks’ gestation was 11.3 (SD +8.8)
months and 11.2 (SD +9.3) months for those
allocated to the calcium and placebo groups,
respectively.
Dietary calcium intake was only estimated
using a triple-pass 24-hour recall at 20 weeks’
gestation. There was no difference in dietary cal-
cium intake at 20 weeks’ gestation between the
groups, those allocated to calcium (n ¼ 143) had
a mean dietary calcium intake of 418.9 (SD ¼
249.2) mg, whereas those allocated to placebo (n
¼ 153) had a mean dietary calcium intake of 435.7
(SD ¼ 348.9) mg.22
Women allocated to calcium had a weight
mean increase of 1.1 (SD +5.5) kg, whereas
women allocated to placebo had a mean increase
of 1.5 (SD +6.1) kg, a mean difference of 0.4 kg
(95%0.4 (1.4 to 0.6); P¼ .408; Table 2). From
admission to 20 weeks, women allocated to cal-
cium had an increase in weight of 3.9 kg (SD
+6.0) and those allocated to placebo 4.0 kg (SD
+7.0), a mean difference of 0.1 kg (95% 0.1
(1.3 to 1.1); P¼ .811; Table 2). From admission
to 32 weeks’ gestation, the weight of women allo-
cated to calcium increased 7.7 kg (SD +6.6) and
those allocated to placebo 8.3 kg (SD +7.3), a
mean difference of 0.6 kg (95% 0.6 (2.2 to
1.0); P ¼ .457).
Table 2 shows changes in body weight from
admission to 8, 20, and 32 weeks’ gestation stra-
tified by baseline BMI categories. Women who
started the trial with BMI equal or higher than 30
had a lower body weight gain at 8 weeks’
Table 1. Comparison of Baseline Characteristics of Women Included in the CAP Trial Study and Women
Included in This Study.a
Placebo Calcium Placebo Calcium
N Mean SD N Mean SD N Mean SD N Mean SD
Maternal age 677 30.4 5.9 678 30.2 5.8 227 29.0 5.0 230 29.7 5.4
Parity 677 2.0 1.1 678 1.9 1.1 227 1.9 1.1 230 2.0 1.1
Weight at ADM (kg) 641 76.9 18.8 649 76.2 18.5 227 74.0 16.3 230 75.8 16.8
Height at ADM (cm) 613 160.0 6.7 617 160.2 6.3 215 159.9 6.4 221 160.7 6.4
BMI at ADM 608 30.1 6.9 610 29.7 7.1 215 28.9 6.2 221 29.3 6.6
Months since last birth
with PE
648 24.6 36.3 645 22.1 29.7 212 20.2 26.2 224 20.9 27.3
Time in study from ADM
to 8 weeks’ gestation
247 11.15 9.07 247 11.16 8.68 227 11.25 9.28 230 11.26 8.79
Country of origin
Argentina 57 (8.4%) 60 (8.8%) 8 (3.5%) 11 4.8
South Africa 479 (70.8%) 477 (70.4%) 150 (66.1%) 147 63.9
Zimbabwe 141 (20.8%) 141 (20.8%) 69 (30.4%) 72 31.3
Abbreviations: ADM, admission; BMI, body mass prepregnancy index; CAP, Calcium And Preeclampsia; PE, preeclampsia.
aMean values with SD.
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gestation (1.0 kg; 95% 1.0 (3.2 to 1.2); P ¼
.330) and at 32 weeks’ gestation (2.1 kg; 95%
2.1 (5.6 to 1.3); P ¼ .225) if they received
calcium as compared to placebo; however, none
of these differences were statistically significant.
Supplementary Table S1 shows compliance of
women measured at 8, 20, and 32 weeks’ gesta-
tion. We did not find any difference in compliance
between calcium and placebo groups at any point.
Between 50% and 60% of women had a compli-
ance of 80% or more with the study supplements.
When considering only participants with a com-
pliance of 80% or more, we also found no statisti-
cally significant differences between the groups
either (Supplementary Table S2). Finally, we ana-
lyzed the effect of calcium supplementation on
body weight by time in the study between admis-
sion to pregnancy, and we found no difference
between the calcium and placebo groups (Supple-
mentary Table S3).
Discussion
This study shows that supplementation with cal-
cium prior to and during early pregnancy was asso-
ciated with a small but consistent reduction in
weight gain in comparison with women receiving
a placebo. Although the results did not achieve our
chosen level of statistical significance, mean val-
ues were consistently lower in the calcium supple-
mentation groups. There was a greater effect in
subgroups of obese and overweight women.
Although this small effect may not seem clinically
relevant, at a population level where a weight gain
at midlife was estimated in 0.27 kg/yr, this effect
could be important.23,24 Moreover, the tendency is
consistent with observations in animal and human
supplementation studies.9,10,25 Also, basic studies
have described the mechanism that can explain the
effect of calcium intake on body weight.26
Three mechanisms by which calcium could
affect body weight have been postulated. Low cal-
cium intake stimulates parathyroid hormone and
1-25 dihydroxyvitamin D secretion to increase
calcium resorption from the bones, reabsorption
from the kidneys, and absorption in the intestine
in order to maintain specific calcium concentra-
tions in extracellular fluids.27,28 However, higher
levels of parathyroid hormone and 1-25 dihydrox-
yvitamin D also stimulate calcium influx into dif-
ferent cell types, including the adipocyte where it
stimulates fatty acid synthase and lipogenesis.27,28









Weight change at 8 weeks’
gestation
227 1.5 (6.1) 230 1.1 (5.5) 0.4 (1.4 to 0.6) .408
BMI at ADM <25 kg/m2 72 0.8 (4.2) 70 1.5 (4.4) 0.7 (0.8 to 2.1) .334
25  BMI at ADM < 30 kg/m2 72 1.7 (5.3) 65 0.8 (4.0) 0.9 (2.5 to 0.7) .261
BMI at ADM  30 kg/m2 83 2.0 (7.9) 95 0.9 (7.0) 1.0 (3.2 to 1.2) .330
Weight change at 20 weeks’
gestation
198 4.0 (7.0) 198 3.9 (6.0) 0.1 (1.3 to 1.1) .811
BMI at ADM <25 kg/m2 62 4.6 (5.7) 60 4.5 4.7) 0.1 (1.9 to 1.8) .916
25  BMI at ADM < 30 kg/m2 63 3.9 (6.6) 53 3.4 (4.4) 0.5 (2.5 to 1.6) .628
BMI at ADM  30 kg/m2 73 3.7 (8.2) 85 3.7 (7.6) 0.0 (2.5 to 2.5) 1.000
Weight change at 32 weeks’
gestation
139 8.3 (7.3) 142 7.7 (6.6) 0.6 (2.2 to 1.0) .457
BMI at ADM <25 kg/m2 44 8.2 (5.4) 42 9.2 (5.5) 1.1 (1.3 to 3.4) .398
25  BMI at ADM < 30 kg/m2 50 8.2 (6.6) 37 8.1 (5.0) 0.1 (2.6 to 2.4) .936
BMI at ADM  30 kg/m2 45 8.6 (9.4) 63 6.5 (7.9) 2.1 (5.6 to 1.3) .225
Abbreviations: ADM, admission; BMI, body mass prepregnancy index.
a Differences were tested using a t test and a P value of .05.
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Low calcium diets have also been linked to insulin
resistance and high blood pressure through similar
collateral effects.26,29-31 In this way, hormones
released to compensate for low serum calcium
levels could produce an increase in blood pressure
and lipogenesis.29 A second postulated mechan-
ism is related to appetite regulation. Higher cal-
cium intakes have been linked to increase in
glucagon-like peptide 1 that reduces appetite.32
Finally, the third mechanism is associated with the
fact that calcium absorption is inefficient; thus, a
large proportion of calcium remains in the intes-
tine where it can bind to bile acids or to fatty acids
impairing their absorption and decreasing avail-
able energy.33-39
A systematic review including 6 studies from
the United States and 1 from Iran with a total of
794 women showed that in obese adults, mainly
nonpregnant women, calcium supplementation
from 6 to 12 months compared to placebo had a
greater effect to reduce body weight (0.74 kg; 95%
CI: 1.00-0.48). These results are similar to the
weight difference found in the obese subgroup of
our study.25 However, the doses used in those stud-
ies were much higher than in our study. Six of the
included studies had a duration of 6 months with a
dose of 1000 mg of elemental calcium per day and
1 a duration of 24 months with a dose of 1500 mg
of elemental calcium per day. The lower dose in
our study may explain the lack of significance.
The results of this study should foster research
on the role of calcium intake on body weight
including basic and clinical studies to assess if
achieving an adequate calcium intake can contrib-
ute to long-term weight reduction. In addition,
adequate calcium intake is important for the pre-
vention of hypertension and preeclampsia and for
bone health maintenance, and it has also been
associated with the reduction of renal stones, cho-
lesterol values, and colorectal cancer.25,29,40-44 It
has been reported that calcium can interfere with
iron absorption in the short term; however, pro-
longed calcium supplementation has proven to
have no effect on iron status over time.45-50 Con-
cerns on the potential increase in atherosclerotic
vascular disease in women receiving calcium sup-
plements, allayed by a systematic review and
meta-analysis including 18 RCTs involving 63
564 elderly women participants, concluded that
calcium supplementation with or without vitamin
D has no effect on coronary heart disease or all-
cause mortality risk.51-54
With the current high prevalence of overweight
and obesity among women of childbearing age and
low calcium intake in numerous low- and middle-
income countries, calcium supplementation might
aid weight management before and during preg-
nancy and assist women to reach their pregnancy
with healthier body weights.55,56
Strengths
This is a RCT with standardized procedures used
in all sites. Women in this study had close follow-
up, and weight and height were measured by the
same research team before and during pregnancy.
Limitations
An important limitation of this analysis is the
small sample size. Our subanalysis was not pow-
ered to detect weight reduction differences smaller
than 1.6 kg that are also clinically relevant at a
population level. It is important to note that the
findings of this study are only applicable to
women with a risk of preeclampsia and not gen-
eralizable to all pregnant women. It has been
shown that obesity, hypertension, and endothelial
dysfunction are risk factors for preeclampsia. In
this way, women in the CAP trial might have had
an increased occurrence of these diseases com-
pared to the general population and therefore dif-
ferent physiological changes.57,58 In addition, we
only had the admission measurement of body
weight before pregnancy for each participant, and
thus, we used body weight measured at 8 weeks as
a proxy of prepregnancy body weight. Finally, we
only measured diet at 20 weeks’ gestation when all
women had finished the trial intervention, which
limited the analysis we can perform with dietary
information.
Conclusion
Even though the clinical relevance of a small
weight reduction at individual level has been ques-
tioned, at a population level, it could help to pre-
vent the observed obesity global trends.23 We
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found that a low dose of calcium supplementation
of 500 mg of elemental calcium per day had no
statistically significant effect on body weight in
women preconceptionally and during early preg-
nancy. However, the smaller increase in body
weight we found in women supplemented with
calcium is consistent with previous human studies
and also is also biologically plausible based upon
prior mechanistic studies. Data from this study
will contribute to the overall body of evidence
on this topic, including systematic reviews of ran-
domized trials.
Appendix A
Calcium And Preeclampsia Study Group
Argentina: Fernando Althabe, José M Belizán,
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lyn Frank, Annmarie de Greeff, Sue Fawcus,
David Hall, Justus Hofmeyr, Mvuseleli Kovane,
Patience Kovane, Theresa Lawrie, Simpiwe Mose,
Nolundi Mshweshwe, Velisa Mqikela, Pamela
Njikelana, Natalia Novikova, Adegboyega Oye-
bajo, Catherine Parker, Angel Phuti, Mandisa
Singata-Madliki, Erika van Papendorp, Xoliswa
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Dannemann, Armando Seuc. United Kingdom:
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Donnay, Sharla Drebit, Jim Roberts. Zimbabwe:
Bothwell Guzha, Emilia Makaza, Sarah Man-
yame, Stephen Munjanja, Eunice Tahuringana.
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cium plus vitamin D supplementation and fat mass
loss in female very low-calcium consumers: poten-
tial link with a calcium-specific appetite control.
Br J Nutr. 2009;101(5):659-663. doi:10.1017/
S0007114508030808
39. Major GC, Chaput JP, Ledoux M, et al. Recent
developments in calcium-related obesity research.
Obes Rev. 2008;9(5):428-445. doi:10.1111/j.1467-
789X.2007.00465.x
40. Hofmeyr GJ, Seuc AH, Betrán AP, et al. The effect
of calcium supplementation on blood pressure in
non-pregnant women with previous pre-eclampsia:
an exploratory, randomized placebo controlled
study. Pregnancy Hypertens. 2015;5(4). doi:10.
1016/j.preghy.2015.04.001
41. Cormick G, Ciapponi A, Cafferata ML, Belizán
JM. Calcium supplementation for prevention of
primary hypertension. Cochrane Database Syst
Rev. 2015;2017(12):e15. doi:10.1002/14651858.
CD010037.pub2
42. Prezioso D, Strazzullo P, Lotti T, et al. Dietary
treatment of urinary risk factors for renal stone
formation. a review of CLU Working Group. Arch
Ital di Urol e Androl. 2015;87(2):105-120. doi:10.
4081/aiua.2015.2.105
43. Heaney RP. Calcium supplementation and inci-
dent kidney stone risk: a systematic review. J Am
Coll Nutr. 2008;27(5):519-527. doi:10.1080/
07315724.2008.10719734
44. Chen C, Ge S, Li S, Wu L, Liu T, Li C. The effects
of dietary calcium supplements alone or with vita-
min D on cholesterol metabolism. J Cardiovasc
Nurs. 2017;32(5):496-506. doi:10.1097/JCN.
0000000000000379
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